Volume : 10, Issue : 06, June – 2023
Title:
01.COMPARATIVE ASSESSMENT OF METHOTREXATE AND CYCLOSPORINE AS THERAPEUTIC APPROACHES FOR SEVERE PSORIASIS: ANALYZING CLINICAL EFFICACY AND OUTCOMES
Authors :
Dr Tasneem Kousar, Dr Muhammad Osama, Dr Tallal Ahmad, Dr Jawadullah Khan, Dr Shehroze Khan Awan, Dr. Abdul Hafeez
Abstract :
Objective: Skin patches that are thick, red, and scaly with a tendency to reoccur over time are the hallmark of the chronic autoimmune illness psoriasis. Cyclosporine and methotrexate have been two widely used therapies for severe psoriasis for a long time. Our goal in this research is to evaluate the clinical efficacy of methotrexate and cyclosporine as treatments for severe psoriasis. We want to learn about their results and provide some insight into how managing this difficult illness could benefit them.
Methods: To learn more about the health of patients who were hospitalized because of severe psoriasis during the previous three years, Mayo Hospital in Lahore thoroughly analyzed their medical data. The goal of this research was to evaluate several outcomes connected to the severity of the illness, including the PASI score for the psoriasis area and severity and the length of hospitalization.
Results: There were 26 patients in the research study in all. With a standard deviation of 24.64, the average decrease in the PASI (Psoriasis Area Severity Index) was determined to be 42.8%. In comparison to the methotrexate group, which had a lower drop in PASI (mean of 43.22% with a standard deviation of 24.4%) than the cyclosporine group (mean of 54.88% with a standard deviation of 12.73%), researchers found. In addition, the patients in the cyclosporine group received therapy for an average of 18.83 days on average, with a standard deviation of 9.39, as opposed to 11.65 days on average, with a standard deviation of 5.91, in the methotrexate group.
Conclusions: Severe psoriasis has been successfully treated with methotrexate and cyclosporine. Patients receiving cyclosporine therapy, however, can have lengthier hospital stays.
Keywords: cyclosporine, methotrexate, psoriasis
Cite This Article:
Please cite this article in press Tasneem Kousar et al, Comparative Assessment Of Methotrexate And Cyclosporine As Therapeutic Approaches For Severe Psoriasis: Analyzing Clinical Efficacy And Outcomes., Indo Am. J. P. Sci, 2023; 10 (06).
Number of Downloads : 10
References:
1. Yasmeen, N., Sawyer, L. M., Malottki, K., Levin, L. Å., Didriksen Apol, E., & Jemec, G. B. (2022). Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. Journal of Dermatological Treatment, 33(1), 204-218.
2. Galluzzo, M., Chiricozzi, A., Cinotti, E., Brunasso, G., Congedo, M., Esposito, M., … & Parodi, A. (2022). Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opinion on Biological Therapy, 22(3), 367-376.
3. Megna, M., Fabbrocini, G., Cinelli, E., Camela, E., & Ruggiero, A. (2022). Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. Journal of Dermatological Treatment, 33(2), 1074-1078.
4. Griffiths, C. E., Papp, K. A., Song, M., Miller, M., You, Y., Shen, Y. K., … & Blauvelt, A. (2022). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. Journal of Dermatological Treatment, 33(2), 848-856.
5. Megna, M., Potestio, L., Fabbrocini, G., & Ruggiero, A. (2022). Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis: Targets and Therapy, 205-212.
6. Thaçi, D., Strober, B., Gordon, K. B., Foley, P., Gooderham, M., Morita, A., … & Gottlieb, A. B. (2022). Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatology and Therapy, 12(2), 495-510.
7. Maurelli, M., Gisondi, P., & Girolomoni, G. (2023). Tailored biological treatment for patients with moderate-to-severe psoriasis. Expert Review of Clinical Immunology, 19(1), 37-43.
8. Chen, Z. T., Chen, R. F., Li, X. L., Wang, Q., Ren, W. W., Shan, D. D., … & Guo, L. H. (2023). The role of ultrasound in screening subclinical psoriatic arthritis in patients with moderate to severe psoriasis. European Radiology, 1-11.
9. Colombo, D., Bianchi, L., Fabbrocini, G., Corrao, S., Offidani, A., Stingeni, L., … & Zagni, E. (2022). Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) study. Dermatologic Therapy, 35(1), e15166.
10. Ruiz‐Villaverde, R., Rodriguez‐Fernandez‐Freire, L., Armario‐Hita, J. C., Pérez‐Gil, A., & Galán‐Gutiérrez, M. (2022). Super responders to guselkumab treatment in moderate‐to‐severe psoriasis: a real clinical practice pilot series. International Journal of Dermatology, 61(8), 1029-1033.
11. Ghalamkarpour, F., Pourani, M. R., Abdollahimajd, F., & Zargari, O. (2022). A case of severe psoriatic erythroderma with COVID-19. Journal of Dermatological Treatment, 33(2), 1111-1113.
12. Megna, M., Potestio, L., Camela, E., Fabbrocini, G., & Ruggiero, A. (2022). Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting. Dermatologic Therapy, 35(9), e15667.
13. Griffiths, C. E., Gooderham, M., Colombel, J. F., Terui, T., Accioly, A. P., Gallo, G., … & Blauvelt, A. (2022). Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatology and Therapy, 12(6), 1431-1446.
14. Ellis, C. N., Neville, S. J., Sayyouh, M., Elder, J. T., Nair, R. P., Gudjonsson, J. E., … & Agarwal, P. P. (2022). Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study. Journal of the American Academy of Dermatology, 86(3), 535-543.
15. Crowley, J. J., Langley, R. G., Gordon, K. B., Pinter, A., Ferris, L. K., Rubant, S., … & Warren, R. B. (2022). Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: subgroup analysis from the immerge study. Dermatology and Therapy, 12(2), 561-575.
16. Lebwohl, M. G., Merola, J. F., Rowland, K., Miller, M., Yang, Y. W., Yu, J., … & Langley, R. G. (2023). Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with greater than 8600 patient-years of exposure. British Journal of Dermatology, ljad115.
17. Cetkovská, P., Dediol, I., Šola, M., Kojanová, M., Trčko, K., Čarija, A., … & Mamun, K. (2023). Apremilast use in severe psoriasis: real-world data from Central and Eastern Europe. Advances in Therapy, 40(4), 1787-1802.
18. Tsiori, S., Rompoti, N., Kontoangelos, K., Papageorgiou, C., Papageorgiou, C., Stratigos, A., & Rigopoulos, D. (2022). Psychopathology and alexithymia in patients with moderate-to-severe psoriasis: development of a novel index with prognostic value. International Journal of Environmental Research and Public Health, 19(7), 4029.
19. Lebwohl, M., Rowland, K., & Miller, M. (2022). 33150 Safety of guselkumab in patients with moderate-to-severe psoriasis: Pooled analyses across clinical studies. Journal of the American Academy of Dermatology, 87(3), AB106.
20. Caldarola, G., Zangrilli, A., Bernardini, N., Bavetta, M., De Simone, C., Graceffa, D., … & Bianchi, L. (2022). Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study. Dermatologic Therapy, 35(6), e15489.
21. Ruiz‐Villaverde, R., Rodriguez‐Fernandez‐Freire, L., Armario‐Hita, J. C., Pérez‐Gil, A., Chinchay, F. V., & Galán‐Gutiérrez, M. (2022). Guselkumab as a switching strategy after anti‐TNFα, anti‐IL17, or anti‐IL12/23 therapies in moderate‐to‐severe psoriasis. Dermatologic Therapy, 35(10), e15760.
22. Ion, A., Dorobanțu, A. M., Popa, L. G., Mihai, M. M., & Orzan, O. A. (2022). Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases. Biology, 11(6), 808.
23. Thaçi, D., Gerdes, S., Du Jardin, K. G., Perrot, J. L., & Puig, L. (2022). Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy, 12(10), 2325-2341.
24. Wang, X., Kaiser, H., Kvist-Hansen, A., McCauley, B. D., Skov, L., Hansen, P. R., & Becker, C. (2022). IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-severe psoriasis. International Journal of Molecular Sciences, 23(1), 555.
25. Dogra, S., Singh, N., Kumar, S., Narang, T., & Handa, S. (2022). Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis. Dermatologic Therapy, 35(8), e15656.
26. Michelucci, A., Manzo Margiotta, F., Panduri, S., Tonini, A., Romanelli, M., Morganti, R., … & Dini, V. (2022). A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatologic Therapy, 35(4), e15339.
27. Yun, J. S., Scardamaglia, L., Tan, C. G., & McCormack, C. J. (2022). Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australasian Journal of Dermatology, 63(2), e155-e158.
28. Adamczyk, M., Bartosińska, J., Raczkiewicz, D., Adamska, K., Adamski, Z., Czubek, M., … & Krasowska, D. (2023). Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland. Journal of Clinical Medicine, 12(4), 1675.
29. Lebwohl, M. G., Soliman, A. M., Yang, H., Wang, J., Hagan, K., Padilla, B., & Pinter, A. (2022). Impact of Risankizumab on PASI90 and DLQI0/1 duration in moderate-to-severe psoriasis: a post hoc analysis of four phase 3 clinical trials. Dermatology and Therapy, 12(2), 407-418.
30. Zozaya, N., Abdalla, F., Alfonso Zamora, S., Balea Filgueiras, J., Carrascosa Carrillo, J. M., Delgado Sánchez, O., … & HIdalgo-Vega, Á. (2022). Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 22(6), 941-953.